| Business Summary | | International
Isotopes
Inc.
is
involved
in
the
production,
marketing,
and
distribution
of
products
used
in
diagnostic
and
therapeutic
nuclear
medicine,
research
and
industry.
Completion
of
the
plans
the
Company
has
developed
will
establish
the
first
independent
commercial
domestic
producer
of
a
full
range
of
finished
radiopharmaceuticals
(on
a
contract
or
joint
venture
basis),
pharmaceutical
grade
radioisotopes,
radioisotopes
and
medical
devices
for
commercial
sale
to
the
nuclear
medicine
industry
for
the
diagnosis
and
therapeutic
treatment
of
cancer
and
other
diseases.
In
November
2000,
the
Company
closed
down
operations
on
its
Linear
Accelerator
(LINAC).
The
Company
will
still
produce
Brachytherapy
seeds,
Iodine
123,
Fluorine
18,
in
addition
to
several
other
radiopharmaceuticals. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | International
Isotopes,
Inc.
is
involved
in
the
production,
marketing,
and
distribution
of
products
used
in
diagnostic
and
therapeutic
nuclear
medicine,
research
and
industry.
For
the
nine
months
ended
9/00,
revenues
rose
78%
to
$4.9
million.
Net
loss
applicable
to
Common
totalled
$27.4
million,
up
from
$10.3
million.
Results
reflect
increased
sales
of
brachytherapy
seeds
and
development
contract
income,
offset
by
an
increase
in
preferred
stock
dividends. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY1999 Pay | |
| David Camp, Ph.D., 50 Chairman | $21K | Steve Laflin Pres,
CEO, Director | -- | Tommy Thompson, 53 Exec.
VP, COO | 170K | Virgil Simmons, 70 Sr.
VP of International Operations, Sec., | -- | Will Lepeska, 61 VP
of Marketing | -- | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|